drugset
drugset / Trial / NCT04808570

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT04808570 ↗

Phase 1/2 Terminated 23 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Timeline

Start
2021-06-05
Primary completion
2023-11-22
Completion
2023-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ-B3525 Small molecule 20 mg Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma